Retsevmo

selpercatinib · Eli Lilly Nederland B.V.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Retsevmo, covering 2026-02-12 to 2026-07-03. Get the full timeline:

Most recent: EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.